Study: Full-Spectrum Cannabis Oil Improves Liver Function and Reduces Disease Markers in Fatty Liver Model
- A study published in Frontiers in Nutrition found that full-spectrum cannabis oil containing CBD and THC (2:1 ratio) may help reverse key markers of metabolic dysfunction-associated steatotic liver disease (MASLD) in female rats.
- Rats fed a sucrose-rich diet developed liver dysfunction characterized by fat buildup, oxidative stress, early fibrosis, and overactivation of the endocannabinoid system, which were significantly improved by cannabis oil treatment.
- The cannabis oil reduced liver fat accumulation, lowered oxidative stress, enhanced mitochondrial fatty acid oxidation, modulated protective NrF2 pathways, suppressed inflammatory NF-κB signaling, and normalized endocannabinoid system activity in the liver.
- These findings highlight the potential of cannabinoid-based therapies for fatty liver disease, especially in females, and call for further research given the previous focus on male models and the complex mechanisms involved.
(Photo credit: Releaf).
A new study published in Frontiers in Nutrition found that a full-spectrum cannabis oil may help reverse key markers of fatty liver disease.
The research examined metabolic dysfunction-associated steatotic liver disease (MASLD), a condition tied to fat buildup in the liver, oxidative stress, and early fibrosis. Using female Wistar rats fed a sucrose-rich diet, researchers tested whether daily oral doses of a cannabis oil containing cannabidiol (CBD) and THC in a 2:1 ratio could mitigate disease progression.
After three weeks, rats given the sucrose-heavy diet developed clear signs of liver dysfunction, including fat accumulation, increased NAFLD activity scores, disrupted lipid metabolism, and elevated oxidative stress. They also showed early indicators of fibrosis and overactivation of the endocannabinoid system, which plays a role in metabolic regulation.
However, those treated with cannabis oil experienced notable improvements across multiple measures. The treatment reduced liver fat accumulation and disease severity scores, improved how the liver processes fats, and boosted mitochondrial fatty acid oxidation. It also significantly lowered oxidative stress and lipid peroxidation, while increasing protective pathways linked to NrF2 and suppressing inflammatory signaling tied to NF-κB.
In addition, researchers found that cannabis oil helped normalize CB1 receptor activity in the liver and restored circulating endocannabinoid levels, suggesting a broader regulatory effect on the body’s endocannabinoid system.
The findings are particularly significant given the lack of female-specific research in this area. According to the study, most prior cannabinoid research on metabolic disorders has relied on male models, leaving potential sex-based differences underexplored.
While the results are limited to an animal model, the study provides evidence that full-spectrum cannabis oil may influence multiple pathways involved in fatty liver disease, including inflammation, oxidative stress, and metabolic dysfunction. Researchers say these findings support further investigation into cannabinoid-based therapies for MASLD, particularly in female populations.